Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Quick Stats
Jan 30, 202646.2
AI Score
HOLD1.52
Volume Ratio
Feb 12, 2026
Next Earnings
10
+ve Days (30d)
20
-ve Days (30d)
CBIO Stock Summary
Last updated Jan 30, 2026
CBIO is currently trading at $9.59, positioned below its 200-day moving average of $None, suggesting bearish momentum. The stock has a 52-week range of $0.15 to $21.4.
Technical Analysis: The 50-day moving average stands at $12.57, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 31.731, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.29, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates CBIO at 46.2/100 with a HOLD recommendation.
CBIO (Crescent Biopharma, Inc. Common Stock) Indicators
Last updated Jan 30, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 31.731 |
| CMF (20) | -0.29 |
| ROC (10) | -23.28 |
| ADX (14) | 21.668 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -0.425 |
| AROONOSC (14) | -50.0 |
| WILLAMS %R (14) | -96.97 |
| MFI (14) | 53.316 |
CBIO Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
CBIO Price vs Max Options Open Interest
CBIO Max Change In Options Open Interest
CBIO Options - Sort by Max open Interest (near term)
31st January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
CBIO Daily Out of Money Options - Sort by Max open Interest (near term)
31st January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
CBIO Daily In the Money Options - Sort by Max open Interest (near term)
31st January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
CBIO Most Active Options by Volume(near term)
31st January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Crescent Biopharma, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
CBIO Moving Averages Analysis
CBIO (Crescent Biopharma, Inc. Common Stock) Simple Moving Averages
Moving Averages are last updated Jan 30, 2026
| Days | MA |
|---|---|
| 10 | 12.11 |
| 20 | 11.71 |
| 30 | 11.86 |
| 50 | 12.57 |
| 100 | 12.5 |
| 200 | None |
CBIO Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 292.5 million |
| Earnings/Share ($) | -- |
| Net Proft Margin (%) | 0 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | 0 |
| EPS Estimate Next Year ($) | 0 |
| WallStreet Target Price ($) | 22 |
| Most Recent Quarter |